Skip to main content
. Author manuscript; available in PMC: 2009 Sep 1.
Published in final edited form as: Leuk Res. 2008 Feb 7;32(9):1439–1447. doi: 10.1016/j.leukres.2007.12.017

Table 2. Characteristics and Treatment Outcomes of Patients Receiving DLI.

Pt # Age WHO Class at Transplant Disease Status at Transplant Time to Relapse (days) Chimerism at Relapse % BM Blasts at Relapse DLI CD3+/kg Dose GVHD Post DLI Outcomes Post DLI
15 57 RCMD Active 227 7% D 2% 1st : 1×107
2nd : 5×107
3rd : 1×108 		Grade II CR×2 yr then relapse
17 65 RCMD Active 52 20-40% D NL 1st: 1×107
2nd: 4.7× 107 		None NR @ 14 mos
21 63 RAEB-1 Active 1455 56-60% D 5% 1×107 Grade II CR at 9 mos
23 64 AML w/MLD Active 130 21-27% D 27% 1×108 None NR Died 1 mos post
24 45 AML from CMML Active 105 5-9% D 20% PB blasts 5×107 Grade III NR: Hospice
29 56 RCMD Active 888 91-94% D 6% 1.13×108 None NR Died 6 mos post
31 56 RAEB-2 Active 923 6-7% D 3% 1st : 1×107
2nd : 5×107 		Grade II CR at 12 mos from 2nd DLI
33 47 AML from CMML Active 123 22-27% D 50%+ blasts 1×108 None NR – Died 1 mos post
36 48 RAEB-1 Active 848 2-7% D 2% 1×107 None NR – Died 2 mos post
42 50 RAEB-2 Active 492 79-85% D 4% Data N/A Grade IV NR – Died 6 mos post

D = Donor Chimerism, CR = Complete Response, NR = No response, Yr = Years, Mos = months